Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

por Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Publicado 2012

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

por Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.
Publicado 2015

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

por Reader, John C., Matthews, Thomas P., Klair, Suki, Cheung, Kwai-Ming J., Scanlon, Jane, Proisy, Nicolas, Addison, Glynn, Ellard, John, Piton, Nelly, Taylor, Suzanne, Cherry, Michael, Fisher, Martin, Boxall, Kathy, Burns, Samantha, Walton, Michael I., Westwood, Isaac M., Hayes, Angela, Eve, Paul, Valenti, Melanie, de Haven Brandon, Alexis, Box, Gary, van Montfort, Rob L. M., Williams, David H., Aherne, G. Wynne, Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Publicado 2011